Clinical trials, measured precisely

Quantitative MRI for ventilation and perfusion across respiratory diseases and trial endpoints.

• Oxygen-enhanced MRI (OE-MRI) ventilation biomarkers
• DCE-MRI perfusion and microvascular measures
• Motion-based ventilation imaging without gases
• Support for hyperpolarised 129Xe studies
• Validated methods across vendors and sites

Functional MRI biomarkers to characterise tumour physiology and therapy response.

• Oxygen-enhanced MRI (OE-MRI) for tumour hypoxia
• DCE-MRI biomarkers of angiogenesis and perfusion
• Diffusion MRI (ADC) for early response detection
• Cross-site protocol standardisation and QA
• Auditable analysis and reporting with VoxelFlow

Imaging biomarkers for inflammatory joint and renal disease with sensitive pharmacodynamic readouts.

• DCE-MRI Ktrans biomarkers of microvascular function
• Joint imaging in rheumatoid arthritis and osteoarthritis
• Renal imaging biomarkers including ASL, T1, T2, ADC
• Hypoxia and pH imaging methods (BOLD, OE-MRI, CEST)
• Sensitive, repeatable measurements with small cohorts

Quantitative MRI and AI-enabled analysis to stratify neurological conditions.

• Atrophy and diffusion metrics for neurodegeneration
• DCE-MRI for subtle blood-brain barrier dysfunction
• Arterial spin labelling (ASL) perfusion methods
• MR spectroscopy and relaxometry
• AI stratification with Queen Square Analytics

Gadoxetate DCE-MRI biomarkers of transporter function and hepatobiliary physiology.

• Gadoxetate DCE-MRI for uptake and efflux kinetics
• Relaxometry (T1, T2, T2*) for tissue status
• TRISTAN project leadership and validation
• FDA biomarker qualification program acceptance
• Study design, QC, analysis, and reporting

Safety-focused imaging biomarkers with rigorous cross-site standardisation and transparent analysis.

• Liver and lung toxicity assays
• Metrology for multi-centre comparability

Spectroscopy protocols and analysis to quantify metabolic and biochemical change.

• Multi-site harmonisation
• Auditable processing workflows

Peer-reviewed evidence demonstrating repeatability and clinical relevance.

• Large publication footprint
• Study interpretation support

Custom imaging software, automation, and analytics built for regulated studies.

• High-performance pipelines
• Secure and auditable tooling

Trial-ready imaging strategy from protocol design to endpoint selection.

• Acquisition standardisation
• Biomarker feasibility planning

Validated analysis and study management platform for quantitative MRI.

• End-to-end QC and audit trails
• Transparent biomarker calculation

Secure data intake, curation, and traceable imaging datasets.

• Multi-centre data workflows
• Compliance-ready archiving

Site qualification, training, and ongoing acquisition support.

• Remote or on-site setup
• Quality feedback loops

Harmonised MR protocols designed for cross-site consistency.

• Vendor-agnostic sequences
• Robust calibration guidance

GxP-aligned processes for reliable, defensible imaging biomarkers.

• SOP-driven operations
• Auditable reporting